Humedics Signs Exclusive Domestic Sales Agreement for 'Kiriel' with One Biogen

Jinhwan Kim, CEO of Humedics (left), Wonil Kim, CEO of One Biogen.

[Asia Economy Reporter Lee Gwan-joo] Humedix announced on the 19th that it has signed a contract with One Biogen for the exclusive domestic sales and product commercialization of the adhesive transparent wound dressing 'Kiriel.'

According to this contract, Humedix will exclusively sell Kiriel in Korea. Kiriel is an adhesive transparent wound dressing used to protect damaged skin by forming a physical barrier over areas where the skin barrier is compromised. It is generally used to protect areas with first-degree burns, dry skin, and other damaged skin barriers.

A Humedix official stated, "Humedix will lead various collaborations through strategic business partnerships with promising new technology companies like One Biogen, which possess proprietary technologies, to newly reshape the skin cosmetic market."

One Biogen is a company specializing in the research, development, and manufacturing of topical medical devices, including moist dressings. It holds numerous proprietary patents related to biocompatible medical polymer materials and currently exports various products such as wound dressings to Europe, the United States, and other regions.

This content was produced with the assistance of AI translation services.